Refeyn, a developer of pioneering mass photometry technology, is expanding its adoption globally across contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs). To showcase this development, Refeyn has launched a new webpage highlighting how leading CROs and CDMOs are redefining process development and manufacturing workflows using mass photometry, and providing researchers with an interactive tool to discover and partner with these organizations.
Refeyn’s Samux™ benchtop mass photometer enables rapid analysis of adeno-associated virus (AAV) samples. Image credit: Refine
The rapid adoption of mass photometry reflects the growing demand for fast, reliable, and cost-effective analyzes for protein and mRNA characterization, antibody development, and viral vector analysis. Introduced just eight years ago, the technology is now cited in nearly 1,500 scientific publications and used by 90 percent of top biopharmaceutical companies. With GMP-compliant software for AAV analysis and approvals from regulatory agencies including the United States Pharmacopeia, China’s NIFDC, and the British Pharmacopoeia, you can confidently deploy mass photometry from initial development to manufacturing and quality control.
Leading CROs and CDMOs are using mass photometry to provide rapid, label-free insight into key quality characteristics such as AAV capsid purity (full/empty/partial ratio), mRNA integrity, purity, and emerging antibody modalities. This allows clients to make earlier, better-informed development decisions and tackle analytical challenges that would otherwise be difficult to achieve using traditional methods, while reducing sample consumption and turnaround times.
Adding mass photometric capabilities to analytical panels accelerates development and manufacturing, reducing the overall cost of new therapies. By working with partners around the world, we help organizations expand access to this technology and ultimately shorten the path from discovery to patient, whether they invest in their own equipment or utilize a trusted service provider. ”
Dr. Gabriela Kiss, Director of Market Development, Refeyn
CROs and CDMOs can partner with Refeyn to differentiate their analyzes and meet the growing demand for faster, higher-quality data, while biopharmaceutical teams can access mass photometry through a growing partner network.
